ISTH: Apixaban non-inferior to conventional treatment for VTE

ISTH: apixaban non-inferior to conventional treatment for VTE
For patients with venous thromboembolism, treatment with oral apixaban is non-inferior to conventional therapy for preventing recurrent venous thromboembolism or death related to venous thromboembolism, according to a study published online July 1 in the New England Journal of Medicine to coincide with presentation at the annual Congress of the International Society on Thrombosis and Haemostasis, held from June 29 to July 4 in Amsterdam.

(HealthDay)—For patients with venous thromboembolism, treatment with oral apixaban is non-inferior to conventional therapy for preventing recurrent venous thromboembolism or death related to venous thromboembolism, according to a study published online July 1 in the New England Journal of Medicine to coincide with presentation at the annual Congress of the International Society on Thrombosis and Haemostasis, held from June 29 to July 4 in Amsterdam.

Giancarlo Agnelli, M.D., from the University of Perugia in Italy, and colleagues conducted a randomized double-blind study to compare apixaban with subcutaneous , followed by warfarin (conventional therapy) in 5,395 patients with acute venous thromboembolism.

The researchers found that the primary efficacy outcome of recurrent symptomatic venous thromboembolism or death related to venous thromboembolism occurred in 2.3 and 2.7 percent of patients in the apixaban and conventional-therapy groups, respectively (relative risk, 0.84; 95 percent confidence interval, 0.60 to 1.18; difference in risk, ?0.4 percentage points; 95 percent confidence interval, ?1.3 to 0.4). For predefined upper limits of the 95 percent confidence intervals for both relative risk and difference in risk, apixaban was non-inferior to conventional therapy. Major bleeding occurred in significantly fewer patients in the apixaban group (0.6 versus 1.8 percent; relative risk, 0.31). The composite outcome of major bleeding and clinically relevant non-major bleeding occurred in significantly fewer patients in the apixaban group (4.3 versus 9.7 percent; relative risk, 0.44).

"A fixed-dose regimen of apixaban alone was non-inferior to for the treatment of acute venous thromboembolism and was associated with significantly less bleeding," the authors write.

The study was funded by Pfizer and Bristol-Myers Squibb, the manufacturers of .

More information: Abstract
Full Text
Editorial
More Information

add to favorites email to friend print save as pdf

Related Stories

Prophylaxis with apixaban feasible for cancer patients

Mar 29, 2012

(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic ...

Proof of added benefit of apixaban in hip replacement

Sep 17, 2012

The clot-inhibiting drug apixaban (trade name: Eliquis) was approved in May 2011 for the prevention of thrombosis (blood clots) after operations to replace a hip or knee joint. In an early benefit assessment pursuant to the ...

Recommended for you

Africans in New York complain of Ebola stigma

5 hours ago

Members of the west African community in New York complained Wednesday that their children were being bullied at school and businesses were losing money because of hysteria over Ebola.

Ebola expert says China at risk, seeks Japan aid

5 hours ago

A scientist who helped to discover the Ebola virus says he is concerned that the disease could spread to China given the large numbers of Chinese workers traveling to and from Africa.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.